glecaprevir/pibrentasvir vs pravastatin
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of glecaprevir/pibrentasvir and pravastatin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Pravastatin ↑ pravastatin Coadministration may increase the concentration of pravastatin. Reduce pravastatin dose by 50% when coadministered with MAVYRET.
Mavyret
Pravachol
Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.
Pravastatin is a drug that lowers cholesterol. It belongs to a class of drugs called statins.
Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. It can be used in people without cirrhosis or with compensated cirrhosis. Mavyret can also treat genotype 1 in people who have already been treated with certain other HCV medicines.
Pravastatin helps lower bad cholesterol and fats (like triglycerides) in your blood, while raising good cholesterol. It can help prevent heart attacks, strokes, and the need for procedures to open blocked arteries. It is used along with a healthy diet to treat high cholesterol and other fat disorders in adults and children 8 years and older.
Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.
Pravastatin works by blocking a substance your body needs to make cholesterol. This helps to lower the amount of cholesterol in your blood. Lowering cholesterol helps to prevent heart disease and stroke.
- • Headache
- • Feeling tired
- • Nausea
- • Muscle pain
- • Nausea
- • Vomiting
- • Diarrhea
- • Headache
- Feeling tired 2,561
- Headache 2,203
- Nausea 1,125
- Itching 653
- Diarrhea 477
- Fatigue 1,262
- Diarrhoea 1,095
- Nausea 954
- Dyspnoea 927
- Headache 842
Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.
Pravastatin can sometimes cause muscle problems, including muscle pain, tenderness, or weakness. In rare cases, this can lead to serious muscle damage called rhabdomyolysis, which can cause kidney failure. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. This medicine can also cause liver problems. Your doctor should do blood tests to check your liver before you start taking pravastatin and if you have any symptoms of liver problems.
It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.
You should not take pravastatin if you are pregnant. It can harm your unborn baby. If you become pregnant while taking pravastatin, stop taking it right away and tell your doctor.
Also Compare, Nearby Drugs
Compare pravastatin with
How to Read This glecaprevir/pibrentasvir vs pravastatin Comparison
glecaprevir/pibrentasvir is classified in the NS3/4A/NS5A Inhibitor (HCV) drug class, while pravastatin sits within the HMG-CoA Reductase Inhibitor (Statin) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, glecaprevir/pibrentasvir has 7,019 submissions while pravastatin has 5,080. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to taking these drugs together can increase the amount of pravastatin in your bloodstream.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for glecaprevir/pibrentasvir or pravastatin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.